Fundraising FoxLengo Therapeutics
Menlo Park, US · Founded 2019 · Delaware corporation · 1 known investors
Find your way into Lengo Therapeutics
Sign up to see every warm intro you have to Lengo Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Lengo Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Frazier-founded precision oncology company developing CNS-penetrant inhibitors; acquired by Blueprint Medicines in 2021.
Founders & leadership
HJ
Helen JenkinsChief Executive Officer
DJ
David JohnsonExecutive
JS
JIA SHENG LOOExecutive
Board
Investors · 1
Reported raises · per SEC filings
Form D private placements$17.7M disclosed across 1 of 2 rounds · 2020–2023
▶$7MofferedApr 2023 · Other TechnologyRule 506(c)
▶$7MofferedApr 2023 · Other Technology
Rule 506(c)Officers, directors & promoters on the filing
- JIA SHENG LOOExecutive Officer, Director, Promoter
- Offering amount
- $7M
- Placement agents
- JIA SHENG LOO
- Incorporated
- Corporation, New York, 2023
- Federal exemptions
- 06c
▶$17.7MraisedApr 2021 · 4 investors · PharmaceuticalsRule 506(b)
▶$17.7MraisedApr 2021 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Daniel Estes, Ph.D.Executive Officer, Director
- Tracy Saxton, Ph.D.Director
- Helen JenkinsExecutive Officer, Director
- Roger Ulrich, Ph.D.Director
- Steve BaileyExecutive Officer
- Anna ChenExecutive Officer
- David JohnsonDirector
- Offering amount
- $17.7M
- Amount sold
- $17.7M
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Lengo Therapeutics do?
- Frazier-founded precision oncology company developing CNS-penetrant inhibitors; acquired by Blueprint Medicines in 2021.
- Who are Lengo Therapeutics's investors?
- Lengo Therapeutics's investors include Frazier Life Sciences.
- How much funding has Lengo Therapeutics raised?
- Lengo Therapeutics has disclosed $17.7M raised across 1 of its 2 known rounds.
- Where is Lengo Therapeutics headquartered?
- Lengo Therapeutics is headquartered in Menlo Park, US.